Investigational drug · Phase 2
PST-611
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Geographic Atrophy, Age - Related Macular Degeneration (AMD).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PST-611"
First trial start
2026
Sep 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PST-611", any sponsor or status.
Conditions studied
As listed on its trial records.
- Geographic Atrophy
- Age - Related Macular Degeneration (AMD)
Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "PST-611" as an intervention, largest first.
- An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic AtrophyNot yet recruiting
EyevensysIndustry
NCT07705568 · 24 participants (planned) · Start Sep 2026 · Primary completion Jun 2028
Drug: PST-611 · For: Geographic Atrophy; Age - Related Macular Degeneration (AMD)
Sites: Grenoble, France; Paris, France · 3 sites in all
- A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular DegenerationCompleted
EyevensysIndustry
NCT07024732 · 8 participants · Start Jun 23, 2025 · Primary completion Apr 7, 2026
Drug: PST-611 · For: Dry Age Related Macular Degeneration
Sites: Grenoble, France; Paris, France
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Geographic Atrophy
- TinlarebantLBS-008Phase 33 trials
Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy
- JNJ-81201887AAVCAGsCD59Phase 32 trials
Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration
- VonaprumentANX007Phase 32 trials
Annexon, Inc. · Geographic Atrophy
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- STL303Phase 22 trials
Sitala Bio LTD · IgAN, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- BI 1584862Phase 21 trial
Boehringer Ingelheim · Geographic Atrophy
- BI 771716Phase 21 trial
Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.